论文部分内容阅读
目的 :了解骨代谢指标骨钙素 (BGP)和游离脱氧吡啶 (DPD)在多发性骨髓瘤 (MM)中的含量变化 ,探讨 BGP和 DPD在 MM患者诊断和治疗方面的意义。方法 :测定 12例 MM患者 (MM组 )治疗前后血清 BGP、钙、磷和碱性磷酸酶 ,以及尿游离脱氧吡啶 /肌苷的含量及其变化 ,以 12例性别和年龄相匹配的体检健康者为对照组。结果 :MM组血清 BGP含量为 (3.41± 0 .6 2 )μg/L ,明显低于对照组的 (4 .5 5± 0 .91)μg/L (P <0 .0 1) ;治疗后 BGP有所升高 ,但差异无显著性意义 (P >0 .0 5 )。MM患者尿游离脱氧吡啶 /肌苷为 (10 .5 3± 1.35 )× 10 - 6 ,显著高于对照组的 (5 .6 1± 1.0 4)× 10 - 6 (P<0 .0 1) ;而治疗后下降为 (8.72± 1.15 )× 10 - 6 ,与治疗前相比差异显著(P <0 .0 1)。血清钙、磷和碱性磷酸酶与对照组无差异 ,治疗前后亦无显著变化。结论 :BGP和 DPD有可能用作了解 MM骨损害程度和评价病情的较敏感指标 ,动态测定 DPD的变化将有助于判断 MM的临床疗效
Objective: To investigate the changes of bone metabolism markers of osteocalcin (BGP) and free deoxypyridine (DPD) in multiple myeloma (MM) and discuss the significance of BGP and DPD in the diagnosis and treatment of MM patients. METHODS: Serum BGP, calcium, phosphorus, and alkaline phosphatase levels, as well as urinary free deoxypyridinol/inosine levels in 12 MM patients (MM group) before and after treatment were measured. The physical and mental health of 12 patients matched for sex and age were determined. The control group. Results: The serum BGP level in MM group was (3.41±0.62)μg/L, which was significantly lower than that in the control group (4.55±0.91) μg/L (P <0.01); BGP increased, but the difference was not significant (P > 0.05). The urinary free deoxypyridinine/inosine was (10.53±1.35)×10 -6 in MM patients, which was significantly higher than that in the control group (5.61±1.04)×10 -6 (P<0.01). After treatment, it decreased to (8.72 ± 1.15) × 10 -6 , which was significantly different from that before treatment (P <0.01). Serum calcium, phosphorus, and alkaline phosphatase did not differ from the control group, and there was no significant change before and after treatment. Conclusion: BGP and DPD may be used as a sensitive index to understand the extent of MM bone damage and evaluate the condition. Dynamic determination of changes in DPD will help determine the clinical efficacy of MM.